<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2052-1707</journal-id>
<journal-id journal-id-type="publisher-id">PRP2</journal-id>
<journal-title-group>
<journal-title>Pharmacology Research &amp; Perspectives</journal-title>
</journal-title-group>
<issn pub-type="epub">2052-1707</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27069625</article-id>
<article-id pub-id-type="pmc">4804321</article-id>
<article-id pub-id-type="doi">10.1002/prp2.195</article-id>
<article-id pub-id-type="publisher-id">PRP2195</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Amitriptyline protects against <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic>‐induced atrophy and reduction in synaptic markers via a Trk‐dependent mechanism</article-title>
<alt-title alt-title-type="left-running-head">E. O'Neill <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="prp2195-cr-0001">
<name>
<surname>O'Neill</surname>
<given-names>Eimear</given-names>
</name>
<xref ref-type="aff" rid="prp2195-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="prp2195-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="prp2195-cr-0002">
<name>
<surname>Kwok</surname>
<given-names>Billy</given-names>
</name>
<xref ref-type="aff" rid="prp2195-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="prp2195-cr-0003">
<name>
<surname>Day</surname>
<given-names>Jennifer S.</given-names>
</name>
<xref ref-type="aff" rid="prp2195-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="prp2195-cr-0004">
<name>
<surname>Connor</surname>
<given-names>Thomas J.</given-names>
</name>
<xref ref-type="aff" rid="prp2195-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="prp2195-cr-0005">
<name>
<surname>Harkin</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="prp2195-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="prp2195-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Neuropsychopharmacology Research Group</named-content>
<institution>School of Pharmacy &amp; Pharmaceutical Sciences and Trinity College Institute of Neuroscience</institution>
<named-content content-type="city">Dublin</named-content>
<country country="IE">Ireland</country>
</aff>
<aff id="prp2195-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Neuroimmunology Research Group</named-content>
<named-content content-type="organisation-division">Department of Physiology</named-content>
<institution>School of Medicine and Trinity College Institute of Neuroscience</institution>
<named-content content-type="city">Dublin</named-content>
<country country="IE">Ireland</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Andrew Harkin, Neuropsychopharmacology Research Group, School of Pharmacy &amp; Pharmaceutical Sciences and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland. Tel: +353‐18968575; Fax: +353‐18963183; E‐mail: <email>aharkin@tcd.ie</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2016</year>
</pub-date>
<volume>4</volume>
<issue>2</issue>
<issue-id pub-id-type="doi">10.1111/prp2.2016.4.issue-2</issue-id>
<elocation-id>e00195</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2015 The Authors. <italic>Pharmacology Research &amp; Perspectives</italic> published by John Wiley &amp; Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution‐NonCommercial‐NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:PRP2-4-e00195.pdf" xlink:type="simple"></self-uri>
<abstract id="prp2195-abs-0001">
<title>Abstract</title>
<p>Neuritic degeneration and synaptic loss are features of both neuroinflammation and neurodegenerative disease. The tricyclic antidepressant amitriptyline has neurotrophic and anti‐inflammatory properties and acts as a novel agonist of the neurotrophin Trk receptors. Primary cortical neurons were treated with amitriptyline, nortriptyline and <styled-content style="fixed-case">NGF</styled-content> and tested for neuronal complexity by Sholl analysis, protein expression by Western immunoblotting, and synapse number by colocalization of pre and postsynaptic makers. Amitriptyline (500 nmol/L) and its active metabolite nortriptyline (50 nmol/L) are found to induce neurite outgrowth in rat primary cortical neurons. Amitriptyline‐induced neurite outgrowth is blocked by inhibition of Trk signaling using Trk antagonist K252a (200 nmol/L) but not by the neurotrophin inhibitor Y1036 (40 <italic>μ</italic>mol/L), indicating that amitriptyline binds directly to the Trk receptor to initiate neurite outgrowth. <styled-content style="fixed-case">MEK</styled-content> inhibitor <styled-content style="fixed-case">PD</styled-content>98059 (10 <italic>μ</italic>mol/L) also blocks amitriptyline‐induced neurite outgrowth, implicating activation of the <styled-content style="fixed-case">MAPK</styled-content> signaling pathway downstream of Trk receptor activation. Furthermore, pretreatment of primary cortical neurons with amitriptyline and nortriptyline prevents the effects of the proinflammatory cytokine <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> (10 ng/mL) on neurite outgrowth and colocalization of synaptic proteins. These findings suggest that amitriptyline and nortriptyline can exert neurotrophic effects in primary cortical neurons via activation of a Trk/<styled-content style="fixed-case">MAPK</styled-content> signaling pathway. These compounds therefore have significant potential to be used in the treatment of neurodegenerative conditions where atrophy and loss of synaptic connections contribute to progression of disease.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="prp2195-kwd-0001">Amitriptyline</kwd>
<kwd id="prp2195-kwd-0002">neurite outgrowth</kwd>
<kwd id="prp2195-kwd-0003">neurotrophin</kwd>
<kwd id="prp2195-kwd-0004">nortriptyline</kwd>
<kwd id="prp2195-kwd-0005"><styled-content style="fixed-case">PSD</styled-content>‐95</kwd>
<kwd id="prp2195-kwd-0006">synaptogenesis</kwd>
<kwd id="prp2195-kwd-0007">synaptophysin</kwd>
<kwd id="prp2195-kwd-0008">Trk receptor</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>European Regional Development Fund</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="15"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>prp2195</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>April 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.6 mode:remove_FC converted:12.04.2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="prp2195-cit-1001" publication-type="journal">
<string-name>
<given-names>E.</given-names>
<surname>O'Neill</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Kwok</surname>
</string-name>, <string-name>
<given-names>J. S.</given-names>
<surname>Day</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Connor</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Harkin</surname>
</string-name>, <article-title>Amitriptyline protects against TNF‐<italic>α</italic>‐induced atrophy and reduction in synaptic markers via a Trk‐dependent mechanism</article-title>, <source/>Pharma Res Per, <volume>4</volume>(<issue>2</issue>), <year>2016</year>, e00195, doi: <ext-link ext-link-type="doi" xlink:href="10.1002/prp2.195">10.1002/prp2.195</ext-link>
</mixed-citation>
</p>
</notes>
</front>
<body>
<def-list id="prp2195-dl-0001" list-content="abbreviations">
<title>Abbreviations</title>
<def-item>
<term>BDNF</term>
<def>
<p>brain‐derived neurotrophic factor</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p>central nervous system</p>
</def>
</def-item>
<def-item>
<term>ERK</term>
<def>
<p>extracellular signal‐related kinase</p>
</def>
</def-item>
<def-item>
<term>IKK</term>
<def>
<p>IκB kinase</p>
</def>
</def-item>
<def-item>
<term>MAPK</term>
<def>
<p>mitogen‐activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>NFκB</term>
<def>
<p>nuclear factor κ B</p>
</def>
</def-item>
<def-item>
<term>NGF</term>
<def>
<p>nerve growth factor</p>
</def>
</def-item>
<def-item>
<term>NT‐3/4</term>
<def>
<p>neurotrophin‐3/4</p>
</def>
</def-item>
<def-item>
<term>p75NTR</term>
<def>
<p>p75 neurotrophin receptor</p>
</def>
</def-item>
<def-item>
<term>PI3K</term>
<def>
<p>phosphoinositide 3‐kinase</p>
</def>
</def-item>
<def-item>
<term>TCA</term>
<def>
<p>tricyclic antidepressant</p>
</def>
</def-item>
<def-item>
<term>TNF‐α</term>
<def>
<p>tumor necrosis factor α</p>
</def>
</def-item>
<def-item>
<term>Trk</term>
<def>
<p>tropomyosin‐receptor‐kinase</p>
</def>
</def-item>
</def-list>
<sec id="prp2195-sec-0001">
<title>Introduction</title>
<p>Amitriptyline is a tricyclic antidepressant that has been in clinical use since 1961 and is still in widespread use today (Leucht et al. <xref ref-type="ref" rid="prp2195-bib-0041">2012</xref>), both as an antidepressant and as a first‐line treatment for neuropathic pain where its role in regulation of neuronal plasticity is thought to be involved in its mechanism of action (Verdu et al. <xref ref-type="ref" rid="prp2195-bib-0065">2008</xref>). As an antidepressant, amitriptyline inhibits reuptake of the monoamine neurotransmitters noradrenaline and serotonin into the presynaptic neuron, thereby increasing their concentrations in the synaptic cleft and contributing to the antidepressant response. This action occurs via blockade of the noradrenaline and serotonin transporters with amitriptyline having a strong affinity for the serotonin transporter and a moderate affinity for the noradrenaline transporter (Tatsumi et al. <xref ref-type="ref" rid="prp2195-bib-0061">1997</xref>). Amitriptyline's mechanism of action in treatment of neuropathic pain is not likely to involve the noradrenaline and serotonin systems, as analgesia is often achieved at lower dosage than that required to achieve an antidepressant effect (Moore et al. <xref ref-type="ref" rid="prp2195-bib-0047">2015</xref>). Amitriptyline has an active metabolite, nortriptyline, which acts in a similar manner to amitriptyline, differing in its selectivity for inhibition of the noradrenaline transporter over the serotonin transporter (Tatsumi et al. <xref ref-type="ref" rid="prp2195-bib-0061">1997</xref>). Nortriptyline is currently prescribed as a second‐generation tricyclic antidepressant for the treatment of major depressive disorder and childhood nocturnal enuresis and is also recommended for treatment of neuropathic pain (Derry et al. <xref ref-type="ref" rid="prp2195-bib-0014">2015</xref>). Amitriptyline and nortriptyline also act as antagonists of various other receptors in the central nervous system (CNS), including serotonergic, <italic>α</italic>
<sub>1</sub>‐adrenergic, histamine and muscarinic cholinergic receptors (Gillman <xref ref-type="ref" rid="prp2195-bib-0024">2007</xref>). It is action on these receptors that leads to the associated adverse effects of these drugs.</p>
<p>More recently, amitriptyline has been shown to act as an agonist of tropomyosin‐receptor‐kinase (Trk) receptors (Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). Trk receptors (TrkA, TrkB, and TrkC) are bound by the neurotrophins: nerve growth factor (NGF), brain‐derived neurotrophic factor (BDNF) and neurotrophins‐3 and ‐4 (NT‐3, NT‐4). Binding of neurotrophins to Trk receptors promotes neuronal survival and differentiation, with TrkA mediating the effects of NGF, TrkB being bound by BDNF, NT‐3 and NT‐4 and TrkC activated by NT‐3. All four neurotrophins can also bind to the p75 neurotrophin receptor (p75NTR), which is thought to induce apoptosis and inhibition of neurite outgrowth, as well as mediating certain cell survival and inflammatory processes (Chao <xref ref-type="ref" rid="prp2195-bib-0008">2003</xref>). It has been demonstrated both in vitro and in vivo that amitriptyline directly binds both TrkA and TrkB receptors and induces their dimerization and activation (Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). Amitriptyline induces neurite outgrowth in the PC12 cell line and injection of amitriptyline into mouse brain prevents excitotoxicity and neuronal apoptosis induced by kainic acid, with the TrkA receptor shown to have the greater role in mediating the neuroprotective effects of amitriptyline in vivo (Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). Amitriptyline has been further demonstrated to induce phosphorylation of the TrkB receptor and to increase production of its cognate ligand, BDNF, in the hippocampus (Chadwick et al. <xref ref-type="ref" rid="prp2195-bib-0007">2011</xref>). In this study, amitriptyline also enhanced cognitive function in a mouse model of Alzheimer's disease which occurred alongside increased neurogenesis in the dentate gyrus in vivo and increased neural progenitor cell development in vitro. Amitriptyline increases expression of <italic>Ndrg4</italic>, a gene that has been demonstrated to enhance neurite outgrowth and remodeling (Hongo et al. <xref ref-type="ref" rid="prp2195-bib-0032">2006</xref>). It has been hypothesized that these increases in markers of neuronal development may indicate a potential mechanism for the observed cognitive enhancement following amitriptyline treatment (Chadwick et al. <xref ref-type="ref" rid="prp2195-bib-0007">2011</xref>). Amitriptyline also has neurotrophic effects, increasing production of glial‐derived neurotrophic factor through activation of fibroblast growth factor signaling (Hisaoka et al. <xref ref-type="ref" rid="prp2195-bib-0031">2011</xref>; Kajitani et al. <xref ref-type="ref" rid="prp2195-bib-0037">2012</xref>) and increasing BDNF expression in the brains of depressed patients (Hellweg et al. <xref ref-type="ref" rid="prp2195-bib-0029">2008</xref>). Additionally, nortriptyline has been demonstrated to increase TrkB phosphorylation in the hippocampus while also increasing BDNF mRNA expression in the dentate gyrus. These changes in neurotrophic signaling were found to correlate well with antidepressant and anxiolytic effects of nortriptyline in a rat model of major depression (Eriksson et al. <xref ref-type="ref" rid="prp2195-bib-0020">2012</xref>).</p>
<p>Inflammation in the CNS is known to be a major contributing factor to neurodegeneration and has been implicated in numerous CNS disorders including Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, and stroke (Allan and Rothwell <xref ref-type="ref" rid="prp2195-bib-0002">2003</xref>; Heneka and O'Banion <xref ref-type="ref" rid="prp2195-bib-0030">2007</xref>; Dantzer et al. <xref ref-type="ref" rid="prp2195-bib-0012">2008</xref>; Lassmann <xref ref-type="ref" rid="prp2195-bib-0040">2008</xref>; McGeer and McGeer <xref ref-type="ref" rid="prp2195-bib-0045">2008</xref>). Growth factors such as the neurotrophins represent potential targets for treatment of inflammatory damage in the CNS. However, the neurotrophins are limited as a therapeutic option due to their lack of blood–brain barrier permeability (Longo and Massa <xref ref-type="ref" rid="prp2195-bib-0042">2013</xref>) and associated adverse effects, such as NGF‐induced hyperalgesia (McKelvey et al. <xref ref-type="ref" rid="prp2195-bib-0046">2013</xref>). For this reason, there is an evident need for brain‐permeable drugs that will reduce neurodegeneration by targeting neuroinflammation. Amitriptyline has been shown to have anti‐inflammatory and antinociceptive effects in animal models of inflammation (Abdel‐Salam et al. <xref ref-type="ref" rid="prp2195-bib-0001">2003</xref>; Sadeghi et al. <xref ref-type="ref" rid="prp2195-bib-0055">2011</xref>). Amitriptyline treatment drives an anti‐inflammatory phenotype by suppressing nitric oxide synthesis, pro‐inflammatory cytokine release (Vismari et al. <xref ref-type="ref" rid="prp2195-bib-0066">2012</xref>), prostaglandin release (Yaron et al. <xref ref-type="ref" rid="prp2195-bib-0068">1999</xref>) neutrophil migration and mast cell secretion of proinflammatory mediators (Clemons et al. <xref ref-type="ref" rid="prp2195-bib-0010">2011</xref>; Gurgel et al. <xref ref-type="ref" rid="prp2195-bib-0026">2013</xref>). Amitriptyline and nortriptyline inhibit tumour necrosis factor <italic>α</italic> (TNF‐<italic>α</italic>) and interleukin‐1<italic>β</italic> release induced by lipopolysaccharide in rat mixed glial cell cultures (Obuchowicz et al. <xref ref-type="ref" rid="prp2195-bib-0051">2006</xref>).</p>
<p>As both the anti‐inflammatory role and action of amitriptyline as a Trk receptor agonist represent potential therapeutic targets for stimulating neuronal growth and synaptogenesis, we hypothesized that amitriptyline and nortriptyline bind directly to Trk receptors on primary neurons to induce neurite outgrowth and increase colocalization of synaptic markers. We used different antagonists of neurotrophic signaling pathways to determine the mechanism by which neurite outgrowth occurs. We also used an inflammatory challenge, namely TNF‐<italic>α</italic>‐induced neuronal atrophy and reduced synaptic colocalization, to determine whether the neurotrophic effects of amitriptyline and nortriptyline are protective in neuroinflammatory conditions. In summary, amitriptyline and nortriptyline were found to increase neurite outgrowth and colocalization of synaptic markers and to protect against the atrophic effects of TNF‐<italic>α</italic>.</p>
</sec>
<sec id="prp2195-sec-0002">
<title>Materials and Methods</title>
<sec id="prp2195-sec-0003">
<title>Materials</title>
<p>Amitriptyline and nortriptyline were obtained from Sigma‐Aldrich, Arklow, Ireland. TNF‐<italic>α</italic> was obtained from R&amp;D Systems Abington, Ireland. K252a was obtained from Sigma‐Aldrich, Ireland. Y1036 was obtained from Millipore, Cork, Ireland. PD98059 was obtained from Tocris Bioscience, Bristol, UK. Anti‐<italic>β</italic>III‐tubulin antibody was obtained from Promega Southampton, UK, antisynaptophysin antibody was obtained from Pierce, Waltham USA, and anti‐PSD‐95 antibody was obtained from Fisher Scientific, Dublin Ireland. Secondary antibodies for fluorescent staining were obtained from Invitrogen, Dun Laoghaire USA, and for Western immunoblotting from GE Life Sciences, Buckinghamshire, UK. Primary antibodies for Western immunoblotting were obtained from Cell Signaling, Danvers USA. Cell culture reagents were obtained from Sarstedt, Wexford, (Ireland) and all other reagents were obtained from Sigma‐Aldrich (Ireland) unless otherwise stated. All animal procedures conformed to the European Council Directive 2010/63/EU and were approved by the Comparative Medicine Ethics Committee of the University of Dublin, Trinity College.</p>
</sec>
<sec id="prp2195-sec-0004">
<title>Preparation of primary cortical neurons</title>
<p>Primary cortical neurons were isolated and prepared from 1‐day‐old Wistar rats (Comparative Medicine Unit, Trinity College Dublin). Briefly, the rats were decapitated, meninges removed and the cortices isolated. Cortical tissue was cross‐chopped in prewarmed complete Neurobasal media (cNBM, 1% (v/v) penicillin/streptomycin, 1% (v/v) Glutamax, 0.1% (v/v) Fungizone and 1% (v/v) B27 supplement) and dissociated in trypsin‐EDTA for 2 min at 37°C. Prewarmed complete Dulbecco's minimal essential media (cDMEM:F12, 10% (v/v) foetal bovine serum, 1% (v/v) penicillin/streptomycin, 0.1% (v/v) Fungizone) was added and the tissue was triturated, followed by centrifugation at 2000g for 3 min at 20°C. The resultant supernatant was discarded and the pellet resuspended in cDMEM. This cell suspension was triturated to a homogeneous suspension, passed through a sterile mesh filter (40 <italic>μ</italic>m) and centrifuged at 2000× rpm for 3 min at 20°C. The supernatant was discarded and the pellet was resuspended in cNBM. The cell suspension was diluted to 3 × 10<sup>5</sup> cells/mL for Sholl analysis and synaptic marker experiments and 1 × 10<sup>6</sup> cells/mL for Western blot experiments and plated onto poly‐d‐lysine‐coated coverslips in 24‐well plates. Cells were cultured in an incubator containing 5% CO<sub>2</sub>, 95% air at 37°C. Neurons were treated after 3 days in vitro (DIV) for Sholl analysis and Western blot experiments and after 18–21 DIV for synaptic marker experiments. All drugs were dissolved in cNBM, where control wells received cNBM alone (+dimethyl sulfoxide (DMSO) vehicle where appropriate).</p>
</sec>
<sec id="prp2195-sec-0005">
<title>Immunocytochemistry and imaging for Sholl analysis</title>
<p>Neuronal cultures were fixed in ice‐cold methanol for 20 min. Non‐specific interactions were blocked using 4% normal goat serum (NGS) in phosphate‐buffered saline (PBS) for 2 h at room temperature. Coverslips were incubated with primary antibody against mouse <italic>β</italic>III‐tubulin (1:1000 in PBS), a specific marker for neurons, at 4°C overnight before incubation with fluorescent secondary antibody goat anti‐mouse Alexa Fluor 488 (1:2000 in PBS) at room temperature for 90 min. Coverslips were mounted on microscope slides using Vectashield mounting medium with DAPI (Vector Labs, Peterborough, UK.). Images were taken using an epifluorescent microscope and AxioVision Rel. 4.8 software (Carl Zeiss MicroImaging, Cambridge, UK.). Neurons were viewed at 200× magnification. Neuronal morphology was measured using Sholl analysis, a widely used method for quantification and graphic representation of the characteristics of neurites (Sholl <xref ref-type="ref" rid="prp2195-bib-0058">1953</xref>). The procedure was adapted from Gutierrez and Davies (<xref ref-type="ref" rid="prp2195-bib-0027">2007</xref>). Care was taken to capture representative images of neurons with clearly distinguishable neurites. Five neurons were analyzed per coverslip and averaged so that 1 coverslip = 1 <italic>n</italic>. The number of primary neurites, the number of neuritic branches, relative neurite length and the Sholl profile of neurons were measured. Primary neurites were defined as neurites extending from the cell body while a neuritic branch was defined where a neurite branched in two for at least 5 <italic>μ</italic>m. Relative neurite length refers to the total number of estimated intersections per neuron and this value is linearly proportional to the metric length of the neuritic arbor (Gutierrez and Davies <xref ref-type="ref" rid="prp2195-bib-0027">2007</xref>). The Sholl profile of a neuron represents the number of neuritic intersections versus the radial distance from the cell soma. Data was collected with the use of a simple computer program (Matlab R2012b, MathWorks, Cambridge, UK.) script.</p>
</sec>
<sec id="prp2195-sec-0006">
<title>Immunocytochemistry and imaging for analysis of synaptic markers</title>
<p>Neuronal cultures were fixed in ice‐cold methanol for 20 min. Nonspecific interactions were blocked and cells permeabilized using 50% NGS in PBS with the addition of 0.2% Triton‐X for 30 min at room temperature. Coverslips were incubated in a cocktail of primary antibodies against rabbit synaptophysin (1:500 in PBS) and mouse PSD‐95 (1:500 in PBS) at 4°C overnight before incubation with fluorescent secondary antibodies goat anti‐mouse Alexa Fluor 488 (1:1000 in PBS) and goat anti‐rabbit Alexa Flour 546 (1:1000 in PBS) at room temperature for 90 min. Coverslips were mounted on microscope slides using Vectashield mounting medium with DAPI. Images were taken using an epifluorescent microscope and AxioVision Rel. 4.8 software. Neurons were viewed at 400× magnification. Images were taken of cells that were at least two cell diameters away from their nearest neighbors. Synaptic colocalization was measured by examining the expression of the pre‐synaptic marker, synaptophysin, and postsynaptic marker, PSD‐95. This procedure was adapted from Ippolito and Eroglu, using the ImageJ analysis programme (National Institutes of Health) with the Puncta Analyzer plug‐in (Ippolito and Eroglu <xref ref-type="ref" rid="prp2195-bib-0034">2010</xref>).</p>
</sec>
<sec id="prp2195-sec-0007">
<title>Western immunoblotting</title>
<p>Neuronal cells were lysed in NP‐40 lysis buffer (50 mmol/L Tris‐HCl, 150 mmol/L NaCl, 1% NP‐40) and protein concentration was determined by the Bradford protein assay method (Bradford <xref ref-type="ref" rid="prp2195-bib-0004">1976</xref>). Samples were equalized and diluted 1:4 in 4× Laemmli sample buffer (1M Tris‐HCl, 25% sodium dodecyl sulphate, 50% glycerol, 10% <italic>β</italic>‐mercaptoethanol, 2% bromophenol blue) and boiled for 5 min at 65° prior to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS‐PAGE) and Western immunoblotting being performed. 10–15 <italic>μ</italic>g total protein was loaded per well. Proteins were separated on 10% gels, transferred onto polyvinylidene fluoride (PVDF) membrane and blocked for 1 h at room temperature with 5% bovine serum albumin (BSA) in Tris‐buffered saline with 0.05% Tween (TBS‐T) prior to incubation at 4°C overnight with primary antibodies against rabbit phosphorylated extracellular signal‐related kinase (ERK), total ERK and <italic>β</italic>‐actin (1:1000 in TBS‐T). Blots were incubated with horseradish peroxidase (HRP)‐conjugated goat anti‐rabbit or goat anti‐mouse secondary antibody (1:2000 in TBS‐T) at room temperature for 1 h. Blots were exposed to Immobilon Western HRP substrate (Millipore) for 5 min and developed using a Fujifilm Luminescent Image Analyzer (LAS‐3000). Protein bands were quantified using ImageJ software. Blots were stripped and reprobed with additional antibodies (three antibodies/blot). The <italic>β</italic>‐actin levels were used as loading controls.</p>
</sec>
<sec id="prp2195-sec-0008">
<title>Statistical analysis of data</title>
<p>All values are expressed as mean ± standard error of the mean (SEM). Data were analyzed using a one‐ or two ‐way analysis of variance (ANOVA) followed, where appropriate, by a Newman–Keuls, Bonferroni (Sholl analysis) or Fisher's Least Significant Difference (LSD) (Western immunoblotting) post hoc test (GB‐Stat). A <italic>P</italic> &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="prp2195-sec-0009">
<title>Results</title>
<sec id="prp2195-sec-0010">
<title>Amitriptyline and nortriptyline induce neurite outgrowth via a direct action on neurons</title>
<p>Amitriptyline has been shown to act as an agonist of Trk receptors and to induce neurite outgrowth in PC12 cells through Trk receptor activation (Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). Therefore, we hypothesized that amitriptyline may act directly on neuronal Trk receptors to induce neurite outgrowth in primary cortical neurons. Primary cortical neurons were treated with amitriptyline (50, 500 nmol/L) or nortriptyline (50, 500 nmol/L) for 24 h. Neuronal complexity was assessed using Sholl analysis. Amitriptyline significantly increased the number of primary neurites (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>a), neuritic length (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>b), number of neuritic branches (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>c) and enhanced the Sholl profile (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>d). Treatment with nortriptyline significantly increased the number of primary neurites (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>a), relative neurite length (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>c) and enhanced the Sholl profile (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0001">1</xref>d).</p>
<fig fig-type="Figure" id="prp2195-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Amitriptyline and nortriptyline increase neurite outgrowth in primary cortical neurons. Effect of amitriptyline and nortriptyline on (A) number of primary neurites, (B) relative neuritic length and (C) number of neuritic branches. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 versus control (one‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman–Keuls). (D) Effect of amitriptyline and nortriptyline on the Sholl profile. ***<italic>P</italic> &lt; 0.001 amitriptyline (50 nmol/L), ###<italic>P</italic> &lt; 0.001 amitriptyline (500 nmol/L), ++<italic>P</italic> &lt; 0.01, +++<italic>P</italic> &lt; 0.001 nortriptyline (50 nmol/L) versus control (two‐way repeated measures <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Bonferroni). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 11–14 coverslips from two independent experiments). Images show representative neurons treated with (A) control and (B) amitriptyline (500 nmol/L) and (C) nortriptyline (50 nmol/L). Neurons are stained with anti‐<italic>β</italic>
<styled-content style="fixed-case">III</styled-content>‐tubulin antibody (white) and <styled-content style="fixed-case">DAPI</styled-content> (blue). Scale bar = 50 <italic>μ</italic>m.</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="PRP2-4-e00195-g001"></graphic>
</fig>
</sec>
<sec id="prp2195-sec-0011">
<title>Inhibition of Trk receptor signaling blocks amitriptyline‐induced neurite outgrowth</title>
<p>To confirm the mechanism by which amitriptyline induces neurite outgrowth, the effect of inhibition of Trk receptor signaling using the antagonist K252a was investigated. K252a is widely used as an inhibitor of Trk signaling (Tapley et al. <xref ref-type="ref" rid="prp2195-bib-0060">1992</xref>). Primary cortical neurons were pretreated with K252a (200 nmol/L) for 30 min followed by stimulation with amitriptyline (500 nmol/L) or NGF (10 ng/mL) for 24 h. Sholl analysis was performed as before. Amitriptyline increased the number of primary neurites, neuritic branches, and relative neurite length as before (Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>). K252a had no effect on neuronal complexity in its own right (Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>). K252a blocked the increase by amitriptyline on the number of primary neurites (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>A), relative neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>C). NGF significantly increased the number of primary neurites (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>A), neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>B) and neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>C). K252a blocked the increase by NGF on the number of primary neurites (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>A), relative neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0002">2</xref>C).</p>
<fig fig-type="Figure" id="prp2195-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Amitriptyline‐induced neurite outgrowth is blocked by inhibition of Trk signaling. Effect of amitriptyline and <styled-content style="fixed-case">NGF</styled-content> on levels of (A) number of primary neurites, (B) relative neuritic length and (C) number of neuritic branches following pre‐treatment with Trk antagonist K252a. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 versus control, ##<italic>P</italic> &lt; 0.01 versus amitriptyline control, ++<italic>P</italic> &lt; 0.01 versus <styled-content style="fixed-case">NGF</styled-content> control (two‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman–Keuls). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 11–14 coverslips from three independent experiments).</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="PRP2-4-e00195-g002"></graphic>
</fig>
</sec>
<sec id="prp2195-sec-0012">
<title>Inhibition of MAPK/ERK signaling blocks amitriptyline‐induced neurite outgrowth</title>
<p>Activation of Trk receptors leads to activation of several signaling pathways. Of these, the mitogen activated protein kinase (MAPK) pathway, is widely associated with neurite outgrowth.</p>
<p>To investigate the involvement of the MAPK signaling pathway in amitriptyline‐induced neurite outgrowth, the ability of the MAPK kinase (MEK) inhibitor PD98059 to attenuate amitriptyline‐induced increase in neuronal complexity was examined. Primary cortical neurons were pretreated with PD98059 (10 <italic>μ</italic>mol/L) for 30 min followed by stimulation with amitriptyline (500 nmol/L) or NGF (10 ng/mL) for 24 h. Sholl analysis was performed as before. Amitriptyline and NGF increased the number of primary neurites, the number of neuritic branches and relative neurite length as before (Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>). PD98059 had no effect on neuronal complexity in its own right (Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>). PD98059 blocked the effect of amitriptyline on the number of primary neurites (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>A), neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>C). PD98059 also blocked the effect of NGF on the number of primary neurites (<italic>P</italic> &lt; 0.05; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>A), neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.05; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>C).</p>
<fig fig-type="Figure" id="prp2195-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Amitriptyline‐ and nortriptyline‐induced increase in neurite outgrowth involves <styled-content style="fixed-case">MAPK</styled-content>/<styled-content style="fixed-case">ERK</styled-content> signaling downstream of Trk activation. Effect of amitriptyline and <styled-content style="fixed-case">NGF</styled-content> on levels of (A) number of primary neurites, (B) relative neuritic length and (C) number of neuritic branches following pretreatment with <styled-content style="fixed-case">MAPK</styled-content> inhibitor <styled-content style="fixed-case">PD</styled-content>98059. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 versus control, #<italic>P</italic> &lt; 0.05, ##<italic>P</italic> &lt; 0.01 versus amitriptyline control, +<italic>P</italic> &lt; 0.05, ++<italic>P</italic> &lt; 0.01 versus <styled-content style="fixed-case">NGF</styled-content> control (two‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman–Keuls). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 12–15 coverslips from three independent experiments). (D) Effect of amitriptyline, nortriptyline and <styled-content style="fixed-case">NGF</styled-content> on <styled-content style="fixed-case">ERK</styled-content>1/2 phosphorylation following pretreatment with Trk antagonist K252a. *<italic>P</italic> &lt; 0.05 versus control, #<italic>P</italic> &lt; 0.05 versus amitriptyline control, ++<italic>P</italic> &lt; 0.01 versus nortriptyline control, $$<italic>P</italic> &lt; 0.01 versus <styled-content style="fixed-case">NGF</styled-content> control (two‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Fisher's <styled-content style="fixed-case">LSD</styled-content>). Data normalized to <italic>β</italic>‐actin levels and expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 10–12 from three independent experiments).</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="PRP2-4-e00195-g003"></graphic>
</fig>
</sec>
<sec id="prp2195-sec-0013">
<title>Inhibition of Trk receptor signaling reduces nortriptyline‐induced ERK phosphorylation</title>
<p>Activation of the MAPK pathway leads to increased phosphorylation of ERK1/2. Therefore, the effect of Trk inhibition on amitriptyline‐, nortriptyline‐ and NGF‐induced ERK1/2 phosphorylation was examined. Primary cortical neurons were pretreated with K252a (200 nmol/L) for 15 min following by stimulation with amitriptyline (500 nmol/L), nortriptyline (50 nmol/L) or NGF (10 ng/mL) for 15 min before neurons were harvested and protein levels of phosphorylated ERK1/2 and total ERK1/2 were detected by Western immunoblotting. Nortriptyline significantly increased phosphorylation of ERK1/2 (<italic>P</italic> &lt; 0.05, Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>D) while amitriptyline and NGF trended towards an increase. K252a significantly reduced ERK phosphorylation levels following amitriptyline (<italic>P</italic> &lt; 0.05; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>D), nortriptyline (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>D) and NGF (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0003">3</xref>D) treatment.</p>
</sec>
<sec id="prp2195-sec-0014">
<title>Amitriptyline increases neurite outgrowth in the presence of inhibited neurotrophin signaling</title>
<p>NGF and BDNF are the cognate ligands for the TrkA and TrkB receptors, respectively. Y1036 is a small molecule inhibitor that binds to NGF and BDNF and prevents their binding to neurotrophin receptors (Eibl et al. <xref ref-type="ref" rid="prp2195-bib-0019">2010</xref>). The effect of inhibition of NGF and BDNF signaling on amitriptyline‐induced neurite outgrowth was examined. Primary cortical neurons were pretreated with Y1036 (40 <italic>μ</italic>mol/L) for 30 min followed by stimulation with amitriptyline (500 nmol/L) or a combination of NGF (10 ng/mL) and BDNF (10 ng/mL). Sholl analysis was performed as before. Amitriptyline increased the number of primary neurites, neuritic branches and relative neurite length as before (Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>). NGF and BDNF increased the number of primary neurites, the number of neuritic branches and relative neurite length (Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>). Y1036 had no effect on neurite outgrowth in its own right (Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>). Y1036 prevented NGF‐ and BDNF‐induced increase in number of primary neurites (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>A), neuritic length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>B) and neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>C). Y1036 prevented amitriptyline‐induced increase in number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>C) but not amitriptyline‐induced increase in primary neurites (Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>A) or neuritic length (Fig. <xref ref-type="fig" rid="prp2195-fig-0004">4</xref>B).</p>
<fig fig-type="Figure" id="prp2195-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>Amitriptyline increases neurite outgrowth in the presence of inhibition of neurotrophin signaling. Effect of amitriptyline and <styled-content style="fixed-case">NGF</styled-content> + BDNF on (A) number of primary neurites, (B) relative neuritic length and (C) number of neuritic branches following pretreatment with neurotrophin antagonist Y1036. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 versus control, ##<italic>P</italic> &lt; 0.01 versus amitriptyline control, ++<italic>P</italic> &lt; 0.01 versus <styled-content style="fixed-case">NGF</styled-content> + <styled-content style="fixed-case">BDNF</styled-content> control (two‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman Keuls). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 11–20 from three independent experiments).</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="PRP2-4-e00195-g004"></graphic>
</fig>
</sec>
<sec id="prp2195-sec-0015">
<title>TNF‐<italic>α</italic> reduces neurite outgrowth in primary cortical neurons</title>
<p>The proinflammatory cytokine TNF‐<italic>α</italic> has been widely demonstrated to contribute to neurodegeneration under inflammatory conditions in the CNS. Primary cortical neurons were treated with TNF‐<italic>α</italic> (1, 10, 100 ng/mL) for 48 h before Sholl analysis was performed as before. TNF‐<italic>α</italic> significantly reduced the number of primary neurites (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0005">5</xref>A), neurite length (<italic>P</italic> &lt; 0.05; Fig. <xref ref-type="fig" rid="prp2195-fig-0005">5</xref>B), neuritic branches (<italic>P</italic> &lt; 0.05; Fig. <xref ref-type="fig" rid="prp2195-fig-0005">5</xref>C) and the Sholl profile (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0005">5</xref>D).</p>
<fig fig-type="Figure" id="prp2195-fig-0005" orientation="portrait" position="float" xml:lang="en">
<label>Figure 5</label>
<caption>
<p>
<styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> decreases neurite outgrowth of primary cortical neurons. Effect of <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> on (A) number of primary neurites, (B) relative neuritic length and (C) number of neuritic branches. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 versus control (one‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman–Keuls). (D) Effect of <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> on the Sholl profile. *<italic>P</italic> &lt; 0.05 <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> (1 ng/mL), #<italic>P</italic> &lt; 0.05, ###<italic>P</italic> &lt; 0.001 <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> (10 ng/mL), ++<italic>P</italic> &lt; 0.01; +++<italic>P</italic> &lt; 0.001 <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> (100 ng/mL) versus control (two‐way repeated measures <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Bonferroni). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 8–12 from two independent experiments). Images show representative neurons treated with (A) control and (B) <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> (10 ng/mL). Neurons are stained with anti‐<italic>β</italic>
<styled-content style="fixed-case">III</styled-content>‐tubulin antibody (white) and <styled-content style="fixed-case">DAPI</styled-content> (blue). Scale bar = 50 <italic>μ</italic>m.</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="PRP2-4-e00195-g005"></graphic>
</fig>
</sec>
<sec id="prp2195-sec-0016">
<title>Amitriptyline, nortriptyline and NGF prevent TNF‐<italic>α</italic>‐induced reduction in neurite outgrowth</title>
<p>As amitriptyline and nortriptyline have been shown to increase neurite outgrowth and enhance neuronal complexity, it was investigated whether amitriptyline and nortriptyline could protect neurons from the reduction in neurite outgrowth induced by TNF‐<italic>α</italic>. Primary cortical neurons were pretreated with amitriptyline (500 nmol/L), nortriptyline (50 nmol/L) or NGF (10 ng/mL) for 2 h followed by addition of TNF‐<italic>α</italic> (10 ng/mL) for 48 h. These doses were selected as they were previously found to be sufficient to increase/decrease neurite outgrowth in this study and previous studies (Gutierrez et al. <xref ref-type="ref" rid="prp2195-bib-0028">2008</xref>; Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). Sholl analysis was performed as before. Amitriptyline, nortriptyline and NGF increased the number of neuritic branches and relative neurite length as before (Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>A, B) but had no effect on primary neurites. TNF‐<italic>α</italic> reduced number of neuritic branches and neurite length as before (Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>A, B) but had no effect on primary neurites. Amitriptyline prevented the reduction in neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>C) induced by TNF‐<italic>α</italic>. Nortriptyline prevented the reduction in neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>C) induced by TNF‐<italic>α</italic>. NGF prevented the reduction in neurite length (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>B) and the number of neuritic branches (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0006">6</xref>C).</p>
<fig fig-type="Figure" id="prp2195-fig-0006" orientation="portrait" position="float" xml:lang="en">
<label>Figure 6</label>
<caption>
<p>Amitriptyline and nortriptyline prevent <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic>‐induced neuronal atrophy. Effect of <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> on (A) number of primary neurites, (B) relative neuritic length and (C) number of neuritic branches following pretreatment with amitriptyline, nortriptyline and <styled-content style="fixed-case">NGF</styled-content>. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 versus control, #<italic>P</italic> &lt; 0.05, ##<italic>P</italic> &lt; 0.01 versus <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> control (two‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman–Keuls). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 12–16 from three independent experiments).</p>
</caption>
<graphic id="nlm-graphic-11" xlink:href="PRP2-4-e00195-g006"></graphic>
</fig>
</sec>
<sec id="prp2195-sec-0017">
<title>Amitriptyline, nortriptyline and NGF increase colocalization of synaptic markers and prevent TNF‐<italic>α</italic>‐induced reduction in colocalization</title>
<p>Loss of synaptic connections is a feature of many neurodegenerative disorders. As amitriptyline and nortriptyline have been shown to increase neurite outgrowth, we examined whether this increase coincided with an increase in colocalization of synaptic markers. We also determined whether amitriptyline and nortriptyline could protect against TNF‐<italic>α</italic>‐induced reduction in colocalization. Primary cortical neurons were treated with amitriptyline (500 nmol/L), nortriptyline (50 nmol/L) or NGF (10 ng/mL) for 24 h before synaptic markers were examined by measurement of colocalization of the presynaptic marker synaptophysin and postsynaptic marker PSD‐95. Amitriptyline (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0007">7</xref>A), nortriptyline (<italic>P</italic> &lt; 0.05; Fig. <xref ref-type="fig" rid="prp2195-fig-0007">7</xref>A) and NGF (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0007">7</xref>A) significantly increased the number of colocalized synaptic puncta. Neurons were treated with TNF‐<italic>α</italic> (10 ng/mL) for 48 h before analysis. TNF‐<italic>α</italic> significantly decreased colocalization (<italic>P</italic> &lt; 0.001; Fig. <xref ref-type="fig" rid="prp2195-fig-0007">7</xref>B). To investigate whether the Trk agonists could protect against reduction in colocalization induced by TNF‐<italic>α</italic>, neurons were pretreated with amitriptyline (500 nmol/L), nortriptyline (50 nmol/L) or NGF (10 ng/mL) for 2 h followed by addition of TNF‐<italic>α</italic> (10 ng/mL) for 48 h before colocalization of synaptic markers was examined. Amitriptyline increased colocalization and TNF‐<italic>α</italic> decreased colocalization as before (Fig. <xref ref-type="fig" rid="prp2195-fig-0007">7</xref>C). Nortriptyline and NGF alone had no effect on colocalization at this timepoint. Amitriptyline, nortriptyline, and NGF significantly prevented reduction in colocalization (<italic>P</italic> &lt; 0.01; Fig. <xref ref-type="fig" rid="prp2195-fig-0007">7</xref>C).</p>
<fig fig-type="Figure" id="prp2195-fig-0007" orientation="portrait" position="float" xml:lang="en">
<label>Figure 7</label>
<caption>
<p>Amitriptyline and nortriptyline prevent <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic>‐induced reduction in colocalization of synaptic markers. (A) Effect of amitriptyline, nortriptyline and <styled-content style="fixed-case">NGF</styled-content> on colocalization of synaptic puncta. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001 versus control (one‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman– Keuls). (B) Effect of <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> on colocalization of synaptic puncta. *<italic>P</italic> &lt; 0.001 versus control (unpaired t‐test). (C) Effect of <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> on colocalization following pretreatment with amitriptyline, nortriptyline and <styled-content style="fixed-case">NGF</styled-content>. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01 versus control, ##<italic>P</italic> &lt; 0.01 versus <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> control (two‐way <styled-content style="fixed-case">ANOVA</styled-content> followed by post hoc Newman–Keuls). Data expressed as mean ± <styled-content style="fixed-case">SEM</styled-content> (<italic>n</italic> = 70–120 neurons from three independent experiments). Images show representative neuron treated with amitriptyline (500 nmol/L) and <styled-content style="fixed-case">TNF</styled-content>‐<italic>α</italic> (10 ng/mL). Neurons are stained with antisynaptophysin (green), anti‐<styled-content style="fixed-case">PSD</styled-content>‐95 (red) and <styled-content style="fixed-case">DAPI</styled-content> (blue). Yellow arrows indicate examples colocalized synaptic puncta. Scale bar = 20 <italic>μ</italic>m. </p>
</caption>
<graphic id="nlm-graphic-13" xlink:href="PRP2-4-e00195-g007"></graphic>
</fig>
</sec>
</sec>
<sec id="prp2195-sec-0018">
<title>Discussion</title>
<p>The results of this study demonstrate, for the first time, that amitriptyline and its active metabolite nortriptyline increase neurite outgrowth and colocalization of synaptic markers in rat primary cortical neurons and have the ability to protect neurons against an atrophic stimulus. The induction of neurite outgrowth by amitriptyline and nortriptyline is comparable to that induced by the endogenous TrkA agonist NGF, as previously reported by our laboratory (Day et al. <xref ref-type="ref" rid="prp2195-bib-0013">2014</xref>). The therapeutic plasma concentration of amitriptyline ranges from 360 to 900 nmol/L (O'Donnell and Shelton <xref ref-type="ref" rid="prp2195-bib-0052">2011</xref>) and brain concentrations are likely to be higher due to the lipophilic nature of the drug. Therefore, the 500 nmol/L concentration of amitriptyline used in this study falls within its therapeutic range. Amitriptyline is metabolized in the liver by N‐demethylation whereby it is converted to nortriptyline, a secondary amine (Breyer‐Pfaff <xref ref-type="ref" rid="prp2195-bib-0005">2004</xref>). The desmethyl metabolite nortriptyline retains biological activity and therefore may also account for part of the activity of amitriptyline. It was found in these studies that amitriptyline and nortriptyline increased neurite outgrowth while having no effect on neuronal viability (data not shown), indicating that these drugs do not simply improve viability but increase the complexity of neuronal structure. It has previously been shown that alternative tricyclic compounds have no effect on neurite outgrowth (Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). In our laboratory, we have also found clomipramine and selective serotonin reuptake inhibitor fluoxetine to have no effect on neurite outgrowth at identical endpoints to those examined with amitriptyline and nortriptyline (data not shown). Amitriptyline‐ and nortriptyline‐induced increase in co‐localization of synaptic markers is a novel finding. While no effect on synaptic growth has previously been reported, amitriptyline has been demonstrated to have effects on synaptic plasticity. Amitriptyline stimulates transcription of the early growth response‐1 (Egr‐1) in glial cells (Chung et al. <xref ref-type="ref" rid="prp2195-bib-0009">2007</xref>). Egr‐1, also known as NGF‐induced protein A, is a plasticity‐related gene that has functions including enhancement of synaptic protein expression (James et al. <xref ref-type="ref" rid="prp2195-bib-0035">2004</xref>). Amitriptyline itself has been found to increase expression of plasticity‐related genes synaptophysin, synaptotagmin, ampiphysin, neogenin, and cAMP response element‐binding protein (CREB) (Drigues et al. <xref ref-type="ref" rid="prp2195-bib-0016">2003</xref>). This increase in synaptic gene expression potentially contributes to the increase in synapse markers observed in this study.</p>
<p>Amitriptyline has previously been found to inhibit neurite outgrowth in cerebral rat and chick embryos (Farbman et al. <xref ref-type="ref" rid="prp2195-bib-0021">1988</xref>). This study involved use of explants which contain immune cells that possibly contribute to the observed reduction in outgrowth. In line with this result, it was found in the present study that conditioned media from amitriptyline‐treated primary cortical mixed glial cells has no effect on neurite outgrowth (data not shown). It is therefore possible that amitriptyline‐induced activation of immune cells, such as microglia which were present in the mixed glial cultures, may have an inhibitory or no effect on neurite outgrowth. This indicates that direct targeting of neurons is necessary to promote outgrowth with amitriptyline and led to the hypothesis that amitriptyline acts on neuronal Trk receptors to induce growth. Inhibition of Trk signaling using antagonist K252a blocked amitriptyline‐induced neurite outgrowth, confirming a Trk receptor role in this mechanism. NGF was utilized as a positive control in this experiment and NGF‐induced increases in neuronal complexity were also blocked by K252a. However, it should be noted that K252a has more recently been demonstrated to inhibit the activity of several other tyrosine and serine/threonine kinases in vitro (Martin et al. <xref ref-type="ref" rid="prp2195-bib-0043">2011</xref>). Therefore, use of more specific Trk inhibitors would be of interest for further studies.</p>
<p>Trk activation results in autophosphorylation of tyrosine residues, recruitment of adaptor proteins and activation of the MAPK and phosphoinositide 3‐kinase (PI3K) pathways (Huang and Reichardt <xref ref-type="ref" rid="prp2195-bib-0033">2003</xref>). The MAPK pathway, in particular the ERK1/2 branch, has been found to be favored following NGF‐induced Trk activation (Segal <xref ref-type="ref" rid="prp2195-bib-0056">2003</xref>) and is also widely implicated in neurite outgrowth (Thomas and Huganir <xref ref-type="ref" rid="prp2195-bib-0063">2004</xref>). Therefore, increased phosphorylation of ERK1/2 was investigated as a marker of increased Trk activation and K252a‐induced reversal of ERK phosphorylation used to confirm the Trk involvement. Nortriptyline significantly increased ERK phosphorylation while amitriptyline and NGF trended towards an increase. K252a significantly reduced amitriptyline‐, nortriptyline‐ and NGF‐induced levels of phosphorylated ERK, demonstrating that Trk receptor activation is involved in the ERK signaling induced by all three compounds and therefore likely involved in their induction of neurite outgrowth. Inhibition of this pathway via the MEK inhibitor PD98059 blocked amitriptyline‐ and NGF‐induced neurotrophic activity, further implicating the Trk/MAPK pathway in induction of neurite outgrowth. Inhibition of neurotrophin signaling using the neurotrophin antagonist Y1036 prevented amitriptyline‐induced increases in neuritic branching but did not prevent amitriptyline‐induced increase in number of primary neurites and neuritic length. The reason for the effect on neuritic branching is unclear, however, the mechanisms underlying neurite extension and branching are not identical (Gallo <xref ref-type="ref" rid="prp2195-bib-0023">2011</xref>) and it is possible that amitriptyline requires some convergence with neurotrophins to induce neuritic branching. Neurotrophin‐induced activation of PI3K signaling leads to formation of axonal branches (Ketschek and Gallo <xref ref-type="ref" rid="prp2195-bib-0039">2010</xref>; Kalil and Dent <xref ref-type="ref" rid="prp2195-bib-0038">2014</xref>) and it is possible that amitriptyline does not induce as potent a stimulation of PI3K signaling. Pretreatment with anti‐NGF and –BDNF antibodies has been shown to fail to block activation of TrkA and TrkB by amitriptyline in primary cortical neurons (Jang et al. <xref ref-type="ref" rid="prp2195-bib-0036">2009</xref>). This suggests that amitriptyline activates Trk receptors independent of neurotrophin action.</p>
<p>Neuroinflammation and the increased expression of proinflammatory cytokines in the CNS have widely been shown to contribute to various neurodegenerative diseases. One of the hallmark characteristics of neuroinflammation is an increased expression of proinflammatory cytokines in the brain, of these TNF‐<italic>α</italic> is among the most prominent (Block and Hong <xref ref-type="ref" rid="prp2195-bib-0003">2005</xref>). Proinflammatory cytokines such as TNF‐<italic>α</italic> contribute to neurodegeneration by increasing immune activation, excitotoxicity and apoptosis (Smith et al. <xref ref-type="ref" rid="prp2195-bib-0059">2012</xref>) as well as by altering glial function (DiProspero et al. <xref ref-type="ref" rid="prp2195-bib-0015">1997</xref>), inhibiting neurotrophic activity (Golz et al. <xref ref-type="ref" rid="prp2195-bib-0025">2006</xref>), reducing neuritic outgrowth (Neumann et al. <xref ref-type="ref" rid="prp2195-bib-0048">2002</xref>) and promoting synaptic degeneration (Centonze et al. <xref ref-type="ref" rid="prp2195-bib-0006">2009</xref>). In this study, TNF‐<italic>α</italic> was found to significantly reduce neurite outgrowth and synaptic colocalization of primary cortical neurons. The reduction in outgrowth was not accompanied by reduction in neuronal viability, indicating that treatment of neurons at 3 DIV with TNF‐<italic>α</italic> specifically affects neurite outgrowth. However, reduction in synaptic marker expression in neurons at 18–21 DIV was accompanied by a reduction in viability (data not shown), indicating that these more mature neurons are more susceptible to TNF‐<italic>α</italic>‐induced damage. TNF‐<italic>α</italic> has previously been shown to inhibit outgrowth via activation of the inhibitory Rho GTPase RhoA, leading to cytoskeletal changes (Mathew et al. <xref ref-type="ref" rid="prp2195-bib-0044">2009</xref>), and also by activation of nuclear factor <italic>κ</italic> B (NF<italic>κ</italic>B) (Gutierrez et al. <xref ref-type="ref" rid="prp2195-bib-0028">2008</xref>). Release of microglial TNF‐<italic>α</italic> coincides with synaptic loss and dendritic spine loss in a model of multiple sclerosis (Centonze et al. <xref ref-type="ref" rid="prp2195-bib-0006">2009</xref>). Reduced neuronal complexity and synaptic connectivity as the result of increased cytokine signaling has the potential to contribute to several dysfunctional conditions in the CNS. These conditions may be improved with the use of drugs with anti‐inflammatory and neurotrophic properties.</p>
<p>Both amitriptyline and nortriptyline protect primary cortical neurons against TNF‐<italic>α</italic>‐induced atrophy and synaptic marker loss. NGF also produced a similar protective effect, indicating that the protection provided by amitriptyline and nortriptyline acts via the Trk pathway. It is possible that amitriptyline and nortriptyline simply compensate for TNF‐<italic>α</italic>‐induced suppression by promoting compensatory outgrowth and synaptic growth. Another mechanism by which this effect may occur is via convergence of the Trk and TNF‐<italic>α</italic> signaling pathways on the NF<italic>κ</italic>B transcription factor system. TNF‐<italic>α</italic> has previously been found to inhibit neurite outgrowth by an NF<italic>κ</italic>B‐dependent mechanism (Gutierrez et al. <xref ref-type="ref" rid="prp2195-bib-0028">2008</xref>; Nolan et al. <xref ref-type="ref" rid="prp2195-bib-0050">2014</xref>). A recent study has found that activation of TrkA by NGF has anti‐inflammatory effects including reduced phosphorylation of NF<italic>κ</italic>B inhibitor I<italic>κ</italic>B and reduced NF<italic>κ</italic>B translocation (Prencipe et al. <xref ref-type="ref" rid="prp2195-bib-0054">2014</xref>). It has also been recently shown that amitriptyline decreases NF<italic>κ</italic>B translocation in an astrocyte cell line (Valera et al. <xref ref-type="ref" rid="prp2195-bib-0064">2014</xref>). It is therefore possible that, through Trk activation, amitriptyline and nortriptyline interfere with NF<italic>κ</italic>B signaling downstream of TNF‐<italic>α</italic>, preventing its detrimental effects on neurons. It is also important to note that the protective effect of amitriptyline and nortriptyline on reduction in synaptic markers occurs in more mature neurons. This highlights the ability of these drugs to protect against neurodegenerative conditions in further developed neurons and may indicate an efficacy in adult neurodegeneration.</p>
<p>Neuronal atrophy and synaptopathy are features of several neurodegenerative disorders that are also associated with a neuroinflammatory component, such as Alzheimer's disease (Nimmrich and Ebert <xref ref-type="ref" rid="prp2195-bib-0049">2009</xref>; Teipel et al. <xref ref-type="ref" rid="prp2195-bib-0062">2013</xref>), Parkinson's disease (Overk and Masliah <xref ref-type="ref" rid="prp2195-bib-0053">2014</xref>) and multiple sclerosis (Wegner et al. <xref ref-type="ref" rid="prp2195-bib-0067">2006</xref>). The loss of synaptic connections and failure of neuronal and neuritic regeneration represent critical obstacles in the treatment of such diseases (Conforti et al. <xref ref-type="ref" rid="prp2195-bib-0011">2007</xref>). Atrophy and synaptopathy are also observed in psychiatric and mood disorders, such as schizophrenia, autism and depression (Duman and Monteggia <xref ref-type="ref" rid="prp2195-bib-0018">2006</xref>; Duman and Aghajanian <xref ref-type="ref" rid="prp2195-bib-0017">2012</xref>). The delayed therapeutic effect of antidepressant drugs has led to research into alternative mechanisms by which antidepressants may act in the brain. Changes involving increased plasticity, neurotrophic signaling and synaptogenesis are thought to occur (Seo et al. <xref ref-type="ref" rid="prp2195-bib-0057">2014</xref>). It is possible that antidepressant drugs such as amitriptyline facilitate neurite outgrowth as a means of enhancing synaptogenesis in the brain. This action may also increase synapse formation when neuronal complexity is challenged in the brain during neuroinflammation. An in vitro system such as that used here is invaluable for the examination of subtle changes in neuronal morphology and an increase in neurite outgrowth in culture can indicate an increased capacity for regeneration in vivo (Fournier et al. <xref ref-type="ref" rid="prp2195-bib-0022">2003</xref>). Therefore, examination of neuritic regeneration and synaptic formation in vivo, while beyond the scope of this work, would be of interest for further studies.</p>
<p>Collectively, the results of this study demonstrate that amitriptyline and its metabolite nortriptyline have the ability to induce neurite outgrowth and an increase in synaptic marker colocalization in primary cortical neurons and can also mitigate the atrophic effects of the proinflammatory cytokine TNF‐<italic>α</italic>. Both compounds therefore demonstrate potential therapeutic benefit as neurotrophic drugs. Use of neurotrophins for treatment of CNS disorders is impeded by their low blood–brain barrier permeability and associated adverse effects. Alternative Trk agonists, such as amitriptyline and nortriptyline, therefore have promising potential to be used in the treatment of inflammatory neurodegenerative conditions.</p>
</sec>
<sec id="prp2195-sec-0020">
<title>Disclosures</title>
<p>None declared.</p>
</sec>
</body>
<back>
<ack id="prp2195-sec-0019">
<title>Acknowledgements</title>
<p>This study was funded under the Programme for Research in Third‐Level Institutions (PRTLI) Cycle 5 of the Higher Education Authority (HEA) and co‐funded under the European Regional Development Fund.</p>
</ack>
<ref-list content-type="cited-references" id="prp2195-bibl-0001">
<title>References</title>
<ref id="prp2195-bib-0001">
<mixed-citation id="prp2195-cit-0001" publication-type="journal">
<string-name>
<surname>Abdel‐Salam</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>Nofal</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>El‐Shenawy</surname>
<given-names>SM</given-names>
</string-name> (<year>2003</year>). <article-title>Evaluation of the anti‐inflammatory and anti‐nociceptive effects of different antidepressants in the rat</article-title>. <source/>Pharmacol Res
<volume>48</volume>: <fpage>157</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">12798668</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0002">
<mixed-citation id="prp2195-cit-0002" publication-type="journal">
<string-name>
<surname>Allan</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Rothwell</surname>
<given-names>NJ</given-names>
</string-name> (<year>2003</year>). <article-title>Inflammation in central nervous system injury</article-title>. <source/>Philos Trans R Soc Lond B Biol Sci
<volume>358</volume>: <fpage>1669</fpage>–<lpage>1677</lpage>.<pub-id pub-id-type="pmid">14561325</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0003">
<mixed-citation id="prp2195-cit-0003" publication-type="journal">
<string-name>
<surname>Block</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>JS</given-names>
</string-name> (<year>2005</year>). <article-title>Microglia and inflammation‐mediated neurodegeneration: multiple triggers with a common mechanism</article-title>. <source/>Prog Neurobiol
<volume>76</volume>: <fpage>77</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">16081203</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0004">
<mixed-citation id="prp2195-cit-0004" publication-type="journal">
<string-name>
<surname>Bradford</surname>
<given-names>MM</given-names>
</string-name> (<year>1976</year>). <article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding</article-title>. <source/>Anal Biochem
<volume>72</volume>: <fpage>248</fpage>–<lpage>254</lpage>.<pub-id pub-id-type="pmid">942051</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0005">
<mixed-citation id="prp2195-cit-0005" publication-type="journal">
<string-name>
<surname>Breyer‐Pfaff</surname>
<given-names>U</given-names>
</string-name> (<year>2004</year>). <article-title>The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man</article-title>. <source/>Drug Metab Rev
<volume>36</volume>: <fpage>723</fpage>–<lpage>746</lpage>.<pub-id pub-id-type="pmid">15554244</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0006">
<mixed-citation id="prp2195-cit-0006" publication-type="journal">
<string-name>
<surname>Centonze</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Muzio</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rossi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cavasinni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>de Chiara</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bergami</surname>
<given-names>A</given-names>
</string-name>, et al. (<year>2009</year>). <article-title>Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis</article-title>. <source/>J Neurosci
<volume>29</volume>: <fpage>3442</fpage>–<lpage>3452</lpage>.<pub-id pub-id-type="pmid">19295150</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0007">
<mixed-citation id="prp2195-cit-0007" publication-type="journal">
<string-name>
<surname>Chadwick</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Caroll</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, et al. (<year>2011</year>). <article-title>Amitriptyline‐mediated cognitive enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity</article-title>. <source/>PLoS ONE
<volume>6</volume>: <fpage>e21660</fpage>.<pub-id pub-id-type="pmid">21738757</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0008">
<mixed-citation id="prp2195-cit-0008" publication-type="journal">
<string-name>
<surname>Chao</surname>
<given-names>MV</given-names>
</string-name> (<year>2003</year>). <article-title>Neurotrophins and their receptors: a convergence point for many signalling pathways</article-title>. <source/>Nat Rev Neurosci
<volume>4</volume>: <fpage>299</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="pmid">12671646</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0009">
<mixed-citation id="prp2195-cit-0009" publication-type="journal">
<string-name>
<surname>Chung</surname>
<given-names>EY</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>YH</given-names>
</string-name> (<year>2007</year>). <article-title>Amitriptyline induces early growth response‐1 gene expression via ERK and JNK mitogen‐activated protein kinase pathways in rat C6 glial cells</article-title>. <source/>Neurosci Lett
<volume>422</volume>: <fpage>43</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">17590509</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0010">
<mixed-citation id="prp2195-cit-0010" publication-type="journal">
<string-name>
<surname>Clemons</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vasiadi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kempuraj</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kourelis</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Vandoros</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</string-name> (<year>2011</year>). <article-title>Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome</article-title>. <source/>J Clin Psychopharmacol
<volume>31</volume>: <fpage>385</fpage>–<lpage>387</lpage>.<pub-id pub-id-type="pmid">21532369</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0011">
<mixed-citation id="prp2195-cit-0011" publication-type="journal">
<string-name>
<surname>Conforti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Adalbert</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Coleman</surname>
<given-names>MP</given-names>
</string-name> (<year>2007</year>). <article-title>Neuronal death: where does the end begin?</article-title>
<source/>Trends Neurosci
<volume>30</volume>: <fpage>159</fpage>–<lpage>166</lpage>.<pub-id pub-id-type="pmid">17339056</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0012">
<mixed-citation id="prp2195-cit-0012" publication-type="journal">
<string-name>
<surname>Dantzer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>O'Connor</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Freund</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Kelley</surname>
<given-names>KW</given-names>
</string-name> (<year>2008</year>). <article-title>From inflammation to sickness and depression: when the immune system subjugates the brain</article-title>. <source/>Nat Rev Neurosci
<volume>9</volume>: <fpage>46</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">18073775</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0013">
<mixed-citation id="prp2195-cit-0013" publication-type="journal">
<string-name>
<surname>Day</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cawley</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aretz</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Kilroy</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gibney</surname>
<given-names>SM</given-names>
</string-name>, et al. (<year>2014</year>). <article-title>Noradrenaline acting on astrocytic beta2‐adrenoceptors induces neurite outgrowth in primary cortical neurons</article-title>. <source/>Neuropharmacology
<volume>77</volume>: <fpage>234</fpage>–<lpage>248</lpage>.<pub-id pub-id-type="pmid">24126345</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0014">
<mixed-citation id="prp2195-cit-0014" publication-type="journal">
<string-name>
<surname>Derry</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wiffen</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Aldington</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>RA</given-names>
</string-name>
<year>2015</year>
<article-title>Nortriptyline for neuropathic pain in adults</article-title>. <source/>Cochrane Database Syst Rev, <volume>1</volume>:<fpage>CD011209</fpage>.<pub-id pub-id-type="pmid">25569864</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0015">
<mixed-citation id="prp2195-cit-0015" publication-type="journal">
<string-name>
<surname>DiProspero</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Meiners</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Geller</surname>
<given-names>HM</given-names>
</string-name> (<year>1997</year>). <article-title>Inflammatory cytokines interact to modulate extracellular matrix and astrocytic support of neurite outgrowth</article-title>. <source/>Exp Neurol
<volume>148</volume>: <fpage>628</fpage>–<lpage>639</lpage>.<pub-id pub-id-type="pmid">9417838</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0016">
<mixed-citation id="prp2195-cit-0016" publication-type="journal">
<string-name>
<surname>Drigues</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Poltyrev</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bejar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Weinstock</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Youdim</surname>
<given-names>MB</given-names>
</string-name> (<year>2003</year>). <article-title>cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs</article-title>. <source/>J Neural Transm
<volume>110</volume>: <fpage>1413</fpage>–<lpage>1436</lpage>.<pub-id pub-id-type="pmid">14666413</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0017">
<mixed-citation id="prp2195-cit-0017" publication-type="journal">
<string-name>
<surname>Duman</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Aghajanian</surname>
<given-names>GK</given-names>
</string-name> (<year>2012</year>). <article-title>Synaptic dysfunction in depression: potential therapeutic targets</article-title>. <source/>Science
<volume>338</volume>: <fpage>68</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">23042884</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0018">
<mixed-citation id="prp2195-cit-0018" publication-type="journal">
<string-name>
<surname>Duman</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Monteggia</surname>
<given-names>LM</given-names>
</string-name> (<year>2006</year>). <article-title>A neurotrophic model for stress‐related mood disorders</article-title>. <source/>Biol Psychiatry
<volume>59</volume>: <fpage>1116</fpage>–<lpage>1127</lpage>.<pub-id pub-id-type="pmid">16631126</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0019">
<mixed-citation id="prp2195-cit-0019" publication-type="journal">
<string-name>
<surname>Eibl</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Chapelsky</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>GM</given-names>
</string-name> (<year>2010</year>). <article-title>Multipotent neurotrophin antagonist targets brain‐derived neurotrophic factor and nerve growth factor</article-title>. <source/>J Pharmacol Exp Ther
<volume>332</volume>: <fpage>446</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">19923440</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0020">
<mixed-citation id="prp2195-cit-0020" publication-type="journal">
<string-name>
<surname>Eriksson</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Delagrange</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Spedding</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Popoli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mathe</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Ogren</surname>
<given-names>SO</given-names>
</string-name>, et al. (<year>2012</year>). <article-title>Emotional memory impairments in a genetic rat model of depression: involvement of 5‐HT/MEK/Arc signaling in restoration</article-title>. <source/>Mol Psychiatry
<volume>17</volume>: <fpage>173</fpage>–<lpage>184</lpage>.<pub-id pub-id-type="pmid">21242991</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0021">
<mixed-citation id="prp2195-cit-0021" publication-type="journal">
<string-name>
<surname>Farbman</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Gonzales</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chuah</surname>
<given-names>MI</given-names>
</string-name> (<year>1988</year>). <article-title>The effect of amitriptyline on growth of olfactory and cerebral neurons in vitro</article-title>. <source/>Brain Res
<volume>457</volume>: <fpage>281</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">3219556</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0022">
<mixed-citation id="prp2195-cit-0022" publication-type="journal">
<string-name>
<surname>Fournier</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Takizawa</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Strittmatter</surname>
<given-names>SM</given-names>
</string-name> (<year>2003</year>). <article-title>Rho kinase inhibition enhances axonal regeneration in the injured CNS</article-title>. <source/>J Neurosci
<volume>23</volume>: <fpage>1416</fpage>–<lpage>1423</lpage>.<pub-id pub-id-type="pmid">12598630</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0023">
<mixed-citation id="prp2195-cit-0023" publication-type="journal">
<string-name>
<surname>Gallo</surname>
<given-names>G</given-names>
</string-name> (<year>2011</year>). <article-title>The cytoskeletal and signaling mechanisms of axon collateral branching</article-title>. <source/>Dev Neurobiol
<volume>71</volume>: <fpage>201</fpage>–<lpage>220</lpage>.<pub-id pub-id-type="pmid">21308993</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0024">
<mixed-citation id="prp2195-cit-0024" publication-type="journal">
<string-name>
<surname>Gillman</surname>
<given-names>PK</given-names>
</string-name> (<year>2007</year>). <article-title>Tricyclic antidepressant pharmacology and therapeutic drug interactions updated</article-title>. <source/>Br J Pharmacol
<volume>151</volume>: <fpage>737</fpage>–<lpage>748</lpage>.<pub-id pub-id-type="pmid">17471183</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0025">
<mixed-citation id="prp2195-cit-0025" publication-type="journal">
<string-name>
<surname>Golz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Uhlmann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ludecke</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Markgraf</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nitsch</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hendrix</surname>
<given-names>S</given-names>
</string-name> (<year>2006</year>). <article-title>The cytokine/neurotrophin axis in peripheral axon outgrowth</article-title>. <source/>Eur J Neurosci
<volume>24</volume>: <fpage>2721</fpage>–<lpage>2730</lpage>.<pub-id pub-id-type="pmid">17156198</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0026">
<mixed-citation id="prp2195-cit-0026" publication-type="journal">
<string-name>
<surname>Gurgel</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Lima‐Junior</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Rabelo</surname>
<given-names>CO</given-names>
</string-name>, <string-name>
<surname>Pessoa</surname>
<given-names>BB</given-names>
</string-name>, <string-name>
<surname>Brito</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Ribeiro</surname>
<given-names>RA</given-names>
</string-name> (<year>2013</year>). <article-title>Amitriptyline, clomipramine, and maprotiline attenuate the inflammatory response by inhibiting neutrophil migration and mast cell degranulation</article-title>. <source/>Rev Bras Psiquiatr
<volume>35</volume>: <fpage>387</fpage>–<lpage>392</lpage>.<pub-id pub-id-type="pmid">24402214</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0027">
<mixed-citation id="prp2195-cit-0027" publication-type="journal">
<string-name>
<surname>Gutierrez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>AM</given-names>
</string-name> (<year>2007</year>). <article-title>A fast and accurate procedure for deriving the Sholl profile in quantitative studies of neuronal morphology</article-title>. <source/>J Neurosci Methods
<volume>163</volume>: <fpage>24</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">17367866</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0028">
<mixed-citation id="prp2195-cit-0028" publication-type="journal">
<string-name>
<surname>Gutierrez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>O'Keeffe</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Gavalda</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gallagher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>AM</given-names>
</string-name> (<year>2008</year>). <article-title>Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the phosphorylation status of p65/RelA</article-title>. <source/>J Neurosci
<volume>28</volume>: <fpage>8246</fpage>–<lpage>8256</lpage>.<pub-id pub-id-type="pmid">18701687</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0029">
<mixed-citation id="prp2195-cit-0029" publication-type="journal">
<string-name>
<surname>Hellweg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ziegenhorn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Heuser</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Deuschle</surname>
<given-names>M</given-names>
</string-name> (<year>2008</year>). <article-title>Serum concentrations of nerve growth factor and brain‐derived neurotrophic factor in depressed patients before and after antidepressant treatment</article-title>. <source/>Pharmacopsychiatry
<volume>41</volume>: <fpage>66</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">18311687</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0030">
<mixed-citation id="prp2195-cit-0030" publication-type="journal">
<string-name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>O'Banion</surname>
<given-names>MK</given-names>
</string-name> (<year>2007</year>). <article-title>Inflammatory processes in Alzheimer's disease</article-title>. <source/>J Neuroimmunol
<volume>184</volume>: <fpage>69</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">17222916</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0031">
<mixed-citation id="prp2195-cit-0031" publication-type="journal">
<string-name>
<surname>Hisaoka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tsuchioka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yano</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Maeda</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kajitani</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Morioka</surname>
<given-names>N</given-names>
</string-name>, et al. (<year>2011</year>). <article-title>Tricyclic antidepressant amitriptyline activates fibroblast growth factor receptor signaling in glial cells: involvement in glial cell line‐derived neurotrophic factor production</article-title>. <source/>J Biol Chem
<volume>286</volume>: <fpage>21118</fpage>–<lpage>21128</lpage>.<pub-id pub-id-type="pmid">21515689</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0032">
<mixed-citation id="prp2195-cit-0032" publication-type="journal">
<string-name>
<surname>Hongo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyazaki</surname>
<given-names>A</given-names>
</string-name> (<year>2006</year>). <article-title>Ndrg4 enhances NGF‐induced ERK activation uncoupled with Elk‐1 activation</article-title>. <source/>J Cell Biochem
<volume>98</volume>: <fpage>185</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">16408304</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0033">
<mixed-citation id="prp2195-cit-0033" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Reichardt</surname>
<given-names>LF</given-names>
</string-name> (<year>2003</year>). <article-title>Trk receptors: roles in neuronal signal transduction</article-title>. <source/>Annu Rev Biochem
<volume>72</volume>: <fpage>609</fpage>–<lpage>642</lpage>.<pub-id pub-id-type="pmid">12676795</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0034">
<mixed-citation id="prp2195-cit-0034" publication-type="journal">
<string-name>
<surname>Ippolito</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Eroglu</surname>
<given-names>C</given-names>
</string-name> (<year>2010</year>). <article-title>Quantifying synapses: an immunocytochemistry‐based assay to quantify synapse number</article-title>. <source/>J Vis Exp
<volume>45</volume>: <fpage>pii2270</fpage>.</mixed-citation>
</ref>
<ref id="prp2195-bib-0035">
<mixed-citation id="prp2195-cit-0035" publication-type="journal">
<string-name>
<surname>James</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Conway</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Thiel</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>BJ</given-names>
</string-name> (<year>2004</year>). <article-title>Egr‐1 modulation of synapsin I expression: permissive effect of forskolin via cAMP</article-title>. <source/>Cell Signal
<volume>16</volume>: <fpage>1355</fpage>–<lpage>1362</lpage>.<pub-id pub-id-type="pmid">15381251</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0036">
<mixed-citation id="prp2195-cit-0036" publication-type="journal">
<string-name>
<surname>Jang</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Weinshenker</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>G</given-names>
</string-name>, et al. (<year>2009</year>). <article-title>Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity</article-title>. <source/>Chem Biol
<volume>16</volume>: <fpage>644</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">19549602</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0037">
<mixed-citation id="prp2195-cit-0037" publication-type="journal">
<string-name>
<surname>Kajitani</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hisaoka‐Nakashima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Morioka</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Okada‐Tsuchioka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kaneko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kasai</surname>
<given-names>M</given-names>
</string-name>, et al. (<year>2012</year>). <article-title>Antidepressant acts on astrocytes leading to an increase in the expression of neurotrophic/growth factors: differential regulation of FGF‐2 by noradrenaline</article-title>. <source/>PLoS ONE
<volume>7</volume>: <fpage>e51197</fpage>.<pub-id pub-id-type="pmid">23227251</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0038">
<mixed-citation id="prp2195-cit-0038" publication-type="journal">
<string-name>
<surname>Kalil</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Dent</surname>
<given-names>EW</given-names>
</string-name> (<year>2014</year>). <article-title>Branch management: mechanisms of axon branching in the developing vertebrate CNS</article-title>. <source/>Nat Rev Neurosci
<volume>15</volume>: <fpage>7</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">24356070</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0039">
<mixed-citation id="prp2195-cit-0039" publication-type="journal">
<string-name>
<surname>Ketschek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gallo</surname>
<given-names>G</given-names>
</string-name> (<year>2010</year>). <article-title>Nerve growth factor induces axonal filopodia through localized microdomains of phosphoinositide 3‐kinase activity that drive the formation of cytoskeletal precursors to filopodia</article-title>. <source/>J Neurosci
<volume>30</volume>: <fpage>12185</fpage>–<lpage>12197</lpage>.<pub-id pub-id-type="pmid">20826681</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0040">
<mixed-citation id="prp2195-cit-0040" publication-type="journal">
<string-name>
<surname>Lassmann</surname>
<given-names>H</given-names>
</string-name> (<year>2008</year>). <article-title>Mechanisms of inflammation induced tissue injury in multiple sclerosis</article-title>. <source/>J Neurol Sci
<volume>274</volume>: <fpage>45</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">18495163</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0041">
<mixed-citation id="prp2195-cit-0041" publication-type="journal">
<string-name>
<surname>Leucht</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huhn</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leucht</surname>
<given-names>S</given-names>
</string-name>
<year>2012</year>
<article-title>Amitriptyline versus placebo for major depressive disorder</article-title>. <source/>Cochrane Database Syst Rev, <volume>12</volume>:<fpage>CD009138</fpage>.<pub-id pub-id-type="pmid">23235671</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0042">
<mixed-citation id="prp2195-cit-0042" publication-type="journal">
<string-name>
<surname>Longo</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Massa</surname>
<given-names>SM</given-names>
</string-name> (<year>2013</year>). <article-title>Small‐molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease</article-title>. <source/>Nat Rev Drug Discov
<volume>12</volume>: <fpage>507</fpage>–<lpage>525</lpage>.<pub-id pub-id-type="pmid">23977697</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0043">
<mixed-citation id="prp2195-cit-0043" publication-type="journal">
<string-name>
<surname>Martin</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Shpiro</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Traynor</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Elliott</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Arthur</surname>
<given-names>JS</given-names>
</string-name> (<year>2011</year>). <article-title>Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays</article-title>. <source/>Neuropharmacology
<volume>61</volume>: <fpage>148</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">21466816</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0044">
<mixed-citation id="prp2195-cit-0044" publication-type="journal">
<string-name>
<surname>Mathew</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Haubert</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kronke</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leptin</surname>
<given-names>M</given-names>
</string-name> (<year>2009</year>). <article-title>Looking beyond death: a morphogenetic role for the TNF signalling pathway</article-title>. <source/>J Cell Sci
<volume>122</volume>: <fpage>1939</fpage>–<lpage>1946</lpage>.<pub-id pub-id-type="pmid">19494121</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0045">
<mixed-citation id="prp2195-cit-0045" publication-type="journal">
<string-name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>McGeer</surname>
<given-names>EG</given-names>
</string-name> (<year>2008</year>). <article-title>Glial reactions in Parkinson's disease</article-title>. <source/>Mov Disord
<volume>23</volume>: <fpage>474</fpage>–<lpage>483</lpage>.<pub-id pub-id-type="pmid">18044695</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0046">
<mixed-citation id="prp2195-cit-0046" publication-type="journal">
<string-name>
<surname>McKelvey</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shorten</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>O'Keeffe</surname>
<given-names>GW</given-names>
</string-name> (<year>2013</year>). <article-title>Nerve growth factor‐mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management</article-title>. <source/>J Neurochem
<volume>124</volume>: <fpage>276</fpage>–<lpage>289</lpage>.<pub-id pub-id-type="pmid">23157347</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0047">
<mixed-citation id="prp2195-cit-0047" publication-type="journal">
<string-name>
<surname>Moore</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Derry</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aldington</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wiffen</surname>
<given-names>PJ</given-names>
</string-name>
<year>2015</year>
<article-title>Amitriptyline for neuropathic pain in adults</article-title>. <source/>Cochrane Database Syst Rev, <volume>7</volume>:<fpage>CD008242</fpage>.<pub-id pub-id-type="pmid">26146793</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0048">
<mixed-citation id="prp2195-cit-0048" publication-type="journal">
<string-name>
<surname>Neumann</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schweigreiter</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rosenkranz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wekerle</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Barde</surname>
<given-names>YA</given-names>
</string-name> (<year>2002</year>). <article-title>Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho‐dependent mechanism</article-title>. <source/>J Neurosci
<volume>22</volume>: <fpage>854</fpage>–<lpage>862</lpage>.<pub-id pub-id-type="pmid">11826115</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0049">
<mixed-citation id="prp2195-cit-0049" publication-type="journal">
<string-name>
<surname>Nimmrich</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ebert</surname>
<given-names>U</given-names>
</string-name> (<year>2009</year>). <article-title>Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta‐amyloid</article-title>. <source/>Rev Neurosci
<volume>20</volume>: <fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">19526730</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0050">
<mixed-citation id="prp2195-cit-0050" publication-type="journal">
<string-name>
<surname>Nolan</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Wyatt</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gw</surname>
<given-names>OK</given-names>
</string-name> (<year>2014</year>). <article-title>The neurite growth inhibitory effects of soluble TNFalpha on developing sympathetic neurons are dependent on developmental age</article-title>. <source/>Differentiation
<volume>88</volume>: <fpage>124</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">25582843</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0051">
<mixed-citation id="prp2195-cit-0051" publication-type="journal">
<string-name>
<surname>Obuchowicz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kowalski</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Labuzek</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Krysiak</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pendzich</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Herman</surname>
<given-names>ZS</given-names>
</string-name> (<year>2006</year>). <article-title>Amitriptyline and nortriptyline inhibit interleukin‐1 release by rat mixed glial and microglial cell cultures</article-title>. <source/>Int J Neuropsychopharmacol
<volume>9</volume>: <fpage>27</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">15963243</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0052">
<mixed-citation id="prp2195-cit-0052" publication-type="book">
<string-name>
<surname>O'Donnell</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Shelton</surname>, <given-names>RC</given-names>
</string-name> (<year>2011</year>). <source/>Drug therapy of depression and anxiety disorders. <publisher-name>McGraw‐Hill Book Companies</publisher-name>, <publisher-loc>New York</publisher-loc>.</mixed-citation>
</ref>
<ref id="prp2195-bib-0053">
<mixed-citation id="prp2195-cit-0053" publication-type="journal">
<string-name>
<surname>Overk</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2014</year>). <article-title>Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease</article-title>. <source/>Biochem Pharmacol
<volume>88</volume>: <fpage>508</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">24462903</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0054">
<mixed-citation id="prp2195-cit-0054" publication-type="journal">
<string-name>
<surname>Prencipe</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Minnone</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Strippoli</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>de Pasquale</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Petrini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Caiello</surname>
<given-names>I</given-names>
</string-name>, et al. (<year>2014</year>). <article-title>Nerve growth factor downregulates inflammatory response in human monocytes through TrkA</article-title>. <source/>J Immunol
<volume>192</volume>: <fpage>3345</fpage>–<lpage>3354</lpage>.<pub-id pub-id-type="pmid">24585880</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0055">
<mixed-citation id="prp2195-cit-0055" publication-type="journal">
<string-name>
<surname>Sadeghi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hajhashemi</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Minaiyan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Movahedian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Talebi</surname>
<given-names>A</given-names>
</string-name> (<year>2011</year>). <article-title>A study on the mechanisms involving the anti‐inflammatory effect of amitriptyline in carrageenan‐induced paw edema in rats</article-title>. <source/>Eur J Pharmacol
<volume>667</volume>: <fpage>396</fpage>–<lpage>401</lpage>.<pub-id pub-id-type="pmid">21645506</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0056">
<mixed-citation id="prp2195-cit-0056" publication-type="journal">
<string-name>
<surname>Segal</surname>
<given-names>RA</given-names>
</string-name> (<year>2003</year>). <article-title>Selectivity in neurotrophin signaling: theme and variations</article-title>. <source/>Annu Rev Neurosci
<volume>26</volume>: <fpage>299</fpage>–<lpage>330</lpage>.<pub-id pub-id-type="pmid">12598680</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0057">
<mixed-citation id="prp2195-cit-0057" publication-type="journal">
<string-name>
<surname>Seo</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>HY</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JE</given-names>
</string-name>, et al. (<year>2014</year>). <article-title>Effects of antidepressant drugs on synaptic protein levels and dendritic outgrowth in hippocampal neuronal cultures</article-title>. <source/>Neuropharmacology
<volume>79</volume>: <fpage>222</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">24296153</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0058">
<mixed-citation id="prp2195-cit-0058" publication-type="journal">
<string-name>
<surname>Sholl</surname>
<given-names>DA</given-names>
</string-name> (<year>1953</year>). <article-title>Dendritic organization in the neurons of the visual and motor cortices of the cat</article-title>. <source/>J Anat
<volume>87</volume>: <fpage>387</fpage>–<lpage>406</lpage>.<pub-id pub-id-type="pmid">13117757</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0059">
<mixed-citation id="prp2195-cit-0059" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Banik</surname>
<given-names>NL</given-names>
</string-name> (<year>2012</year>). <article-title>Role of pro‐inflammatory cytokines released from microglia in neurodegenerative diseases</article-title>. <source/>Brain Res Bull
<volume>87</volume>: <fpage>10</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">22024597</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0060">
<mixed-citation id="prp2195-cit-0060" publication-type="journal">
<string-name>
<surname>Tapley</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lamballe</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Barbacid</surname>
<given-names>M</given-names>
</string-name> (<year>1992</year>). <article-title>K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors</article-title>. <source/>Oncogene
<volume>7</volume>: <fpage>371</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">1312698</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0061">
<mixed-citation id="prp2195-cit-0061" publication-type="journal">
<string-name>
<surname>Tatsumi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Groshan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Blakely</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Richelson</surname>
<given-names>E</given-names>
</string-name> (<year>1997</year>). <article-title>Pharmacological profile of antidepressants and related compounds at human monoamine transporters</article-title>. <source/>Eur J Pharmacol
<volume>340</volume>: <fpage>249</fpage>–<lpage>258</lpage>.<pub-id pub-id-type="pmid">9537821</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0062">
<mixed-citation id="prp2195-cit-0062" publication-type="journal">
<string-name>
<surname>Teipel</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Grothe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lista</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Toschi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Garaci</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Hampel</surname>
<given-names>H</given-names>
</string-name> (<year>2013</year>). <article-title>Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease</article-title>. <source/>Med Clin North Am
<volume>97</volume>: <fpage>399</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">23642578</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0063">
<mixed-citation id="prp2195-cit-0063" publication-type="journal">
<string-name>
<surname>Thomas</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Huganir</surname>
<given-names>RL</given-names>
</string-name> (<year>2004</year>). <article-title>MAPK cascade signalling and synaptic plasticity</article-title>. <source/>Nat Rev Neurosci
<volume>5</volume>: <fpage>173</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">14976517</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0064">
<mixed-citation id="prp2195-cit-0064" publication-type="journal">
<string-name>
<surname>Valera</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ubhi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mante</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Masliah</surname>
<given-names>E</given-names>
</string-name> (<year>2014</year>). <article-title>Antidepressants reduce neuroinflammatory responses and astroglial alpha‐synuclein accumulation in a transgenic mouse model of multiple system atrophy</article-title>. <source/>Glia
<volume>62</volume>: <fpage>317</fpage>–<lpage>337</lpage>.<pub-id pub-id-type="pmid">24310907</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0065">
<mixed-citation id="prp2195-cit-0065" publication-type="journal">
<string-name>
<surname>Verdu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Decosterd</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Buclin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stiefel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Berney</surname>
<given-names>A</given-names>
</string-name> (<year>2008</year>). <article-title>Antidepressants for the treatment of chronic pain</article-title>. <source/>Drugs
<volume>68</volume>: <fpage>2611</fpage>–<lpage>2632</lpage>.<pub-id pub-id-type="pmid">19093703</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0066">
<mixed-citation id="prp2195-cit-0066" publication-type="journal">
<string-name>
<surname>Vismari</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Alves</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Muscara</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Palermo‐Neto</surname>
<given-names>J</given-names>
</string-name> (<year>2012</year>). <article-title>A possible role to nitric oxide in the anti‐inflammatory effects of amitriptyline</article-title>. <source/>Immunopharmacol Immunotoxicol
<volume>34</volume>: <fpage>578</fpage>–<lpage>585</lpage>.<pub-id pub-id-type="pmid">22208160</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0067">
<mixed-citation id="prp2195-cit-0067" publication-type="journal">
<string-name>
<surname>Wegner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Esiri</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Chance</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Palace</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Matthews</surname>
<given-names>PM</given-names>
</string-name> (<year>2006</year>). <article-title>Neocortical neuronal, synaptic, and glial loss in multiple sclerosis</article-title>. <source/>Neurology
<volume>67</volume>: <fpage>960</fpage>–<lpage>967</lpage>.<pub-id pub-id-type="pmid">17000961</pub-id></mixed-citation>
</ref>
<ref id="prp2195-bib-0068">
<mixed-citation id="prp2195-cit-0068" publication-type="journal">
<string-name>
<surname>Yaron</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Shirazi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Judovich</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Levartovsky</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Caspi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yaron</surname>
<given-names>M</given-names>
</string-name> (<year>1999</year>). <article-title>Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures</article-title>. <source/>Arthritis Rheum
<volume>42</volume>: <fpage>2561</fpage>–<lpage>2568</lpage>.<pub-id pub-id-type="pmid">10616001</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>